Astellas Pharma Inc.’s Xospata (gilteritinib) has received its first approval globally, in Japan for FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML), marking the first commercial entry of another option in the increasingly competitive AML space as a varied range of new therapies move to market.
The oral FLT3 (FMS-like tyrosine kinase 3) inhibitor was filed for approval in the indication in Japan only in March,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?